George Abercrombie joins Ziopharm's board
This article was originally published in Scrip
Ziopharm Oncology (US) has appointed George Abercrombie to its board of directors. He will also serve as a member of the board’s compensation committee, as well as the nominating and corporate governance committee. The company has also elected Dr Murray Brennan chairman of the board. Mr Abercrombie most recently served as president and CEO of Roche North America and has more than 30 years' experience in the pharmaceutical industry. Before joining Roche in 2001, Mr Abercrombie was senior vice-president of commercial operations at Glaxo Wellcome.
You may also be interested in...
Pink Sheet Podcast: COVID Vaccine In Adolescents, CMS Drug Pricing Moves, Standard Care In Clinical Trials
Pink Sheet reporters and editors discuss the US FDA decision to lower the eligibility age for the Pfizer/BioNTech COVID-19 vaccine, CMS drug pricing project plans, and mid-stream standard of care changes in drug development.
Keeping Track: US FDA Approves Heron’s Zynrelef In Post-Op Pain; Amgen/AZ Submit Tezepelumab For Severe Asthma
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Some ACIP members argued woman older than 50 should also be singled out in warning for Johnson & Johnson’s COIVD-19 vaccine and said that people need to be more clearly told they can get alternative vaccines that don’t have this risk.